What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

Annals of Oncology

Volumn 23, Issue SUPPL.8, 2012, Pages

  Reck, M ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Antibody; Antigen specific vaccines; Extensive disease small cell lung cancer (ED SCLC); Immunotherapy; Non small cell lung cancer (NSCLC); T cell modulation

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; EMEPEPIMUT S; ETOPOSIDE; IMMUNOMODULATING AGENT; IPILIMUMAB; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 SPECIFIC CANCER IMMUNOTHERAPEUTIC; MUCIN 1; NIVOLUMAB; PACLITAXEL; PLACEBO; TALACTOFERRIN; UNCLASSIFIED DRUG;

ANEMIA; ARTHRALGIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNO ONCOLOGY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR CELL; TUMOR IMMUNOLOGY; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; LACTOFERRIN; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PACLITAXEL;

EID: 84865567620     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds260     Document Type: Conference Paper

References (50)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Molina JR, Yang P, Cassivi SD et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594.
3. National Cancer Institute NSCLC Treatment. Non-Small Cell Lung Cancer Treatment (PDQ®). wwwcancergov/cancertopics/pdq/treatment/non-small-celllung/ healthprofessional/page2. 2011.
4. Silvestri GA, Tanoue LT, Margolis ML et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123: 147S-156S.
5. Bonanno L, Favaretto A, Rugge M et al. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011; 71: 2231-2246.
6. Caponi S, Vasile E, Ginocchi L et al. Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clin Lung Cancer 2010; 11: 320-327.
7. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
8. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 68-70.
9. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
10. Bearz A, Berretta M, Lleshi A et al. Target therapies in lung cancer. J Biomed Biotechnol 2011; 2011: 921231.
11. Burris HA, III. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 2009; 28(Suppl 1): S4-S13.
12. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
13. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
14. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
15. Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410-4417.
16. Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-280.
17. Al-Shibli KI, Donnem T, Al-Saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220-5227.
18. Kawai O, Ishii G, Kubota K et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387-1395.
19. Zhuang X, Xia X, Wang C et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010; 18: 24-28.
20. Petersen RP, Campa MJ, Sperlazza J et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107: 2866-2872.
21. Shimizu K, Nakata M, Hirami Y et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5: 585-590.
22. Koyama K, Kagamu H, Miura S et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008; 14: 6770-6779.
23. Zitvogel L, Apetoh L, Ghiringhelli F et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.
24. Aymeric L, Apetoh L, Ghiringhelli F et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855-858.
25. Gridelli C, Rossi A, Maione P et al. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009; 14: 909-920.
26. Gure AO, Chua R, Williamson B et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062.
27. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II nonsmall cell lung cancer (NSCLC). J Clin Oncol 2007; 25: Abstract 7554.
28. Kayashima H, Toshima T, Okano S et al. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice. J Immunol 2010; 185: 698-708.
29. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10: 371-374.
30. Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-651.
31. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 6674-6681.
32. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007; 13: s4652-s4654.
33. Powell E, Chow LQ. BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer. Expert Rev Respir Med 2008; 2: 37-45.
34. Jonasch E, Stadler WM, Bukowski RM et al. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 2008; 113: 72-77.
35. Digumarti R, Wang Y, Raman G et al. A randomized, double-blind, placebocontrolled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011; 6: 1098-1103.
36. Artym J, Zimecki M, Kuryszko J et al. Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice. Stem Cells Dev 2005; 14: 548-555.
37. Dial EJ, Dohrman AJ, Romero JJ et al. Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. J Pharm Pharmacol 2005; 57: 93-99.
38. Troost FJ, Saris WH, Brummer RJ. Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 2003; 57: 1579-1585.
39. Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
40. Agata Y, Kawasaki A, Nishimura H et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
41. Ascierto PA, Simeone E, Sznol M et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37: 508-516.
42. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011; 350: 17-37.
43. Zhang Y, Huang S, Gong D et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010; 7: 389-395.
44. Mu CY, Huang JA, Chen Y et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-688.
45. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer- preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-439.
46. Sznol M, Powderly J, Smith D et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010; 28 (Abstract 2506).
47. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283.
48. Lynch T, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in non-small cell lung cancer: analysis by baseline histology in a phase 2 trial. In Presented at World Conference on Lung Cancer (WCLC) 2011, abstr 701.
49. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-Line treatment in extensive disease-small cell lung cancer (ED-SCLC): results from a phase 2 trial. In Presented at World Conference on Lung Cancer (WCLC) 2011, abstr 1365.
50. Oze I, Hotta K, Kiura K et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009; 4: e7835.